Skip to main content
Clinical Trials/IRCT20210823052264N4
IRCT20210823052264N4
Recruiting
Phase 3

Comparison of Efficacy of Intravenous Versus Intramuscular Injection Meglumine Antimoniate in patients of Cutaneous Leishmaniasis

CMH Quetta0 sites90 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
CMH Quetta
Enrollment
90
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
CMH Quetta

Eligibility Criteria

Inclusion Criteria

  • All patients with biopsy proven leishmaniasis plus any of the following: has lesion(s) located in sites not compatible with local treatment for example eyelids
  • lesions in which scaring would be disabling or severely disfiguring like on face
  • lesions that will have difficulting in healing like on lower limb or over a joint
  • lesions involving mucosa or cartilage
  • lesion \=4 cm
  • lesion with sporotrichoid spread
  • multiple lesions

Exclusion Criteria

  • patients allergic to antimonials
  • the lesion is already self\-curing
  • pregnant and breast feeding women
  • those who refused to accept the diagnostic procedures
  • patients having mucosal, mucocutaneous or visceral leishmaniasis
  • Patients with comorbidity (diabetes, hypertension,chronic liver disease,chronic kidney disease) and/or immunosuppression
  • Patients with baseline ECG abnormalities/Heart disease

Outcomes

Primary Outcomes

Not specified

Similar Trials